Betrixaban (BT), a highly selective direct oral inhibitor of Factor Xa (FXa), is an o-aminobenzamide structural compound developed by Merck for the prevention of venous thromboembolism and related complications in acutely ill patients (Patel et al., 2016). This evidence concerns the gene F10 and venous thromboembolism.